Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Semin Cancer Biol. 2021 Jan 18;82:120–133. doi: 10.1016/j.semcancer.2020.12.016

Fig. 7. Persistent and increased LRIG1 expression in CRPC.

Fig. 7.

(A) Heterogeneous LRIG1 mRNA expression in CRPC. Shown are the relative LRIG1 mRNA levels in CRPC compared to corresponding hormone-naïve PCa in 3 Oncomine datasets. LRIG1 was upregulated in the Tomlins dataset (FC = 2.359; p = 0.009) and showed reduced trend in the Best dataset (FC= −1.635; p = 0.095) whereas LRIG1 did not change in Holzbeirlein dataset (FC = 1.029; p = 0.483). (B) Discordant LRIG1 and AR expression and persistently high LRIG1 expression in patient CRPC. Shown are matched IHC images of AR and LRIG1 in the whole-mount slides of 4 patient CRPC specimens (adapted with permission from [100]). Note that most CRPC cells lost AR expression but retained high levels of LRIG1. (C) Persistent LRIG1 expression in CRPC xenograft models. Whole cell lysates (60 μg/lane) prepared from 4 pairs of androgen-dependent (AD) and androgen-independent (AI; castration-resistant) xenograft tumors (lanes 1-8) and from 1 pair of in vitro castrated (i.e., CDSS for 48 h) LNCaP cells (lanes 9-10) were used in WB analysis of the molecules indicated. (D) Alterations of LRIG1 in an in vitro castration model. As detailed in [108], LNCaP cells were subjected to 3 regimens of long-term castration in culture, i.e., CDSS (charcoal dextran stripped serum), ENZA (enzalutamide; 10 μM), or CDSS plus bica (bicalutamide; 20 μM) for the time intervals indicated (w, week; m, month). Whole cell lysates (60 μg/lane) were used in WB analysis of the molecules indicated. *, cleaved ~110-kD and 100-kD LRIG1 ECD fragments. The arrow indicates the 60-kD ECD fragment.